STOCK TITAN

Veracyte, Inc. - VCYT STOCK NEWS

Welcome to our dedicated page for Veracyte news (Ticker: VCYT), a resource for investors and traders seeking the latest updates and insights on Veracyte stock.

Veracyte, Inc. (symbol: VCYT) is a pioneering genomic diagnostics company dedicated to significantly enhancing patient care through innovative diagnostic solutions. The company specializes in developing and providing genomic diagnostic products and services that improve clinical outcomes by resolving the uncertainties inherent in traditional diagnostic methods.

Veracyte's core business revolves around creating tests that offer more accurate diagnoses without resorting to risky, costly, and often unnecessary surgeries. By employing top-tier scientific rigor, state-of-the-art tools, and the brightest minds in the field, Veracyte delivers diagnostic solutions that bring clarity and assurance to patients and physicians alike.

The company's product portfolio includes the Afirma analysis, Percepta, Envisia, and other cutting-edge diagnostic tests. These products are designed to tackle diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. Veracyte's diagnostic tests are distinguished by their ability to provide conclusive results where traditional methods fall short, thereby sparing patients from unnecessary surgical procedures.

Recent achievements highlight Veracyte's commitment to innovation and excellence. The company consistently introduces evidence that sets new standards in genomic tests, fundamentally altering current clinical practice norms. This commitment to scientific excellence ensures that Veracyte remains at the forefront of the genomic diagnostics industry.

Veracyte's impact extends beyond just clinical outcomes; it significantly influences the lives of both patients and physicians by offering a clearer path forward. Through continuous research, strategic partnerships, and an unwavering dedication to improving patient care, Veracyte stands out as a leader in the genomic diagnostics field.

Rhea-AI Summary

Veracyte reported its third quarter 2024 financial results, showing a 29% increase in total revenue to $115.9 million and a 34% rise in testing revenue to $109.5 million. The company achieved a net income of $15.2 million, a 151% improvement year-over-year, with adjusted EBITDA growing by 117% to $27.3 million. Testing volume increased by 24% to 36,792 tests, driven by strong performance in Decipher and Afirma tests. Decipher revenue grew by 48%, while Afirma revenue increased by 19%. Product revenue and biopharmaceutical revenue saw declines of 21% and 23%, respectively. Veracyte raised its full-year 2024 revenue guidance to $442-$445 million, representing 22%-23% growth. The company expects year-end cash and equivalents to be between $280-$285 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.05%
Tags
-
Rhea-AI Summary

Veracyte (VCYT) has announced its participation in four major investor conferences in November. The cancer diagnostics company will conduct fireside chats at the UBS Healthcare Conference (November 12th, 2:45 PM ET), Guggenheim Inaugural Healthcare Innovation Conference (November 13th, 3:00 PM ET), Wolfe Research Healthcare Conference (November 19th, 1:40 PM ET), and Stephens Annual Investor Conference (November 20th, 4:00 PM ET). Live audio webcasts will be available on Veracyte's investor website, with replays accessible for 90 days after each presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.61%
Tags
conferences
-
Rhea-AI Summary

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, has announced the release date for its third quarter 2024 financial results. The company will disclose these results after the market closes on Wednesday, November 6, 2024.

Following the release, Veracyte's management team will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day. This event will provide a general business update and discuss the financial results. Investors and interested parties can access the live webcast through the company's website or via the provided link: https://edge.media-server.com/mmc/p/kzh3s376.

For those unable to attend the live event, a webcast replay will be made available on Veracyte's investor relations website. Conference call dial-in information can be obtained by registering at the provided link.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
Rhea-AI Summary

Veracyte, Inc. (Nasdaq: VCYT) announced new data from the VANDAAM trial showing that the Decipher Prostate Genomic Classifier accurately predicts aggressive prostate cancer in African American men with early-stage disease. The findings were presented at ASTRO 2024 in Washington, D.C.

Key points:

  • African American men are 70% more likely to be diagnosed with prostate cancer and twice as likely to die from it compared to white men.
  • The study included 226 men (113 African American and 113 non-African American) with low- or intermediate-risk prostate cancer.
  • Patients with high Decipher test scores were eight times more likely to have biochemical recurrence within 2 years.
  • Results showed no significant difference between African American and non-African American men.

This study is the first prospective clinical trial examining genomic risk-stratification in African American men, potentially helping to narrow the prostate cancer disparity gap.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
none
-
Rhea-AI Summary

Veracyte (NASDAQ: VCYT) presented new data at ESMO 2024 showing that its Decipher Prostate Genomic Classifier predicts chemotherapy benefit in patients with metastatic prostate cancer. The findings, from an ancillary study of the phase 3 STAMPEDE trial, support Veracyte's plan to expand the Decipher Prostate test to metastatic disease.

Key findings include:

  • Higher Decipher scores were associated with increased risk of death
  • Patients with higher scores showed a 36% reduction in death risk with docetaxel addition
  • The test predicted benefit regardless of cancer volume

Veracyte plans to offer the test for metastatic prostate cancer in early 2025, pending Medicare reimbursement. This expansion demonstrates the power of Veracyte's Diagnostics Platform in delivering high-performing cancer tests and generating evidence for reimbursement and adoption.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, has announced the appointment of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately. Mr. Shafer, with over 40 years of experience in healthcare technologies, will serve on the Compensation Committee. Dr. Miller, a scientist and entrepreneur focusing on AI, chemistry, and biology, will join the Regulatory and Compliance Committee.

Mr. Shafer's background includes roles as chairman and CEO of Cerner and CEO of Philips North America. Dr. Miller is the co-founder and CEO of Iambic Therapeutics and a former tenured professor at Caltech. Both new board members expressed enthusiasm for Veracyte's mission and potential impact on cancer diagnostics and patient care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
management
Rhea-AI Summary

Veracyte (Nasdaq: VCYT) has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. CEO Marc Stapley and CFO Rebecca Chambers will engage in a fireside chat on Thursday, September 5, at 2:35 p.m. Eastern Time.

Investors and interested parties can access a live audio webcast of the presentation through Veracyte's website at http://investor.veracyte.com/events-presentations. For those unable to attend the live event, a replay of the webcast will be available for 90 days following the presentation.

This participation highlights Veracyte's commitment to engaging with the investment community and sharing insights about the company's progress and future prospects in the healthcare sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
conferences
-
Rhea-AI Summary

Veracyte (Nasdaq: VCYT), a leading cancer diagnostics company, has been named a Bay Area Top Workplace by the San Francisco Chronicle for the 11th consecutive year. This recognition is based solely on employee feedback gathered through a confidential survey administered by Energage, measuring various aspects of employee experience.

The survey assesses themes such as employee respect, support, growth opportunities, and empowerment. Marc Stapley, Veracyte's CEO, expressed honor in receiving this award, emphasizing the company's commitment to its employees and its vision of transforming cancer care globally. Veracyte believes that its employees are important in guiding clinicians and focusing on advancing cancer care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
none
-
Rhea-AI Summary

Veracyte reported a 27% increase in total revenue for Q2 2024, reaching $114.4 million, driven by robust performance of Decipher and Afirma tests.

Testing revenue grew by 31%, while test volume increased by 23% to 39,023. Net income rose to $5.7 million, up 168%, and adjusted EBITDA was $24.0 million, representing 21% of revenue.

Decipher Prostate test volumes surged to nearly 19,900, aided by updated NCCN guidelines. Afirma test volume was approximately 15,700, bolstered by new Medicare coverage.

Total gross margin improved to 68%, and non-GAAP gross margin to 71%. Despite a 3% decrease in product revenue and a 22% decline in biopharmaceutical revenue, operational cash generation was strong at $26.7 million, ending the quarter with $235.9 million in cash and equivalents.

The company has updated its 2024 financial outlook, raising full-year revenue guidance to $432-$438 million and expecting year-end cash reserves of $260-$270 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.97%
Tags
Rhea-AI Summary

Veracyte (Nasdaq: VCYT) has announced that it will release its second quarter 2024 financial results after market close on Tuesday, August 6, 2024. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss the results and provide a general business update. Investors and interested parties can access the live webcast from Veracyte's website or via a provided link. A webcast replay will be available after the broadcast on the company's investor relations page. For those who prefer to join by phone, dial-in registration is available through a separate link.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.34%
Tags

FAQ

What is the current stock price of Veracyte (VCYT)?

The current stock price of Veracyte (VCYT) is $36.775 as of November 8, 2024.

What is the market cap of Veracyte (VCYT)?

The market cap of Veracyte (VCYT) is approximately 1.7B.

What does Veracyte, Inc. specialize in?

Veracyte, Inc. specializes in genomic diagnostics to improve patient care by resolving inconclusive results from traditional diagnostic methods.

What products does Veracyte offer?

Veracyte offers genomic diagnostic products such as Afirma, Percepta, and Envisia, targeting diseases like thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis.

How do Veracyte's tests improve clinical outcomes?

Veracyte's tests provide accurate diagnoses, reducing the need for risky and unnecessary surgeries by resolving ambiguity in traditional diagnostic methods.

What recent achievements has Veracyte accomplished?

Veracyte has consistently introduced evidence that sets new standards in genomic tests, changing today's clinical practice standards.

Who benefits from Veracyte's genomic diagnostic solutions?

Both patients and physicians benefit as Veracyte's tests offer clearer diagnostic paths, improving overall patient care and reducing unnecessary medical procedures.

In which diseases does Veracyte focus its diagnostic solutions?

Veracyte focuses on diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis.

What sets Veracyte apart from traditional diagnostic companies?

Veracyte leverages top-tier scientific rigor, advanced tools, and unmatched expertise to deliver unprecedented diagnostic accuracy without unnecessary surgeries.

How does Veracyte impact clinical practice standards?

Veracyte's innovative genomic tests provide evidence that fundamentally alters clinical practice standards, ensuring more accurate and less invasive diagnosis methods.

What is the significance of Veracyte's Afirma analysis?

The Afirma analysis is a key product in Veracyte's portfolio, offering accurate diagnosis for conditions like thyroid cancer, thus avoiding unnecessary surgeries.

Why is Veracyte considered a leader in genomic diagnostics?

Veracyte leads the industry due to its innovative solutions, consistent introduction of new evidence, and significant impact on improving patient care and clinical practices.

Veracyte, Inc.

Nasdaq:VCYT

VCYT Rankings

VCYT Stock Data

1.74B
76.45M
0.82%
105.25%
4.04%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
SOUTH SAN FRANCISCO